查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1679310

2030 年近視治療市場預測：按類型、治療方法、給藥途徑、年齡層、最終用戶和地區進行的全球分析

Myopia Treatment Market Forecasts to 2030 - Global Analysis By Type (Simple Myopia,High Myopia, Pathological Myopia and Other Types), Treatment, Route of Administration, Age Group, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球近視治療市場預計在 2024 年達到 12,5231 億美元，到 2030 年將達到 22,6615.8 億美元，預測期內的複合年成長率為 10.39%。近視治療是指採用各種方法減緩、停止或矯正近視的發展。治療方案包括處方眼鏡或隱形眼鏡、角膜塑型鏡（角膜重塑鏡片）、阿托品眼藥水，以及LASIK或 PRK 等屈光矯正手術。近視管理策略，特別是針對兒童，旨在透過改變生活方式（例如增加戶外活動和減少螢幕時間）來減緩近視的發展。近視管理的進步集中在創新的鏡片和藥物方法，以預防高度近視相關的併發症，如視網膜剝離和青光眼。

提高認知和診斷

透過擴大職場和學校的篩檢舉措，可以早期發現病例。診斷技術的改進使得能夠準確識別和快速做出反應。人們對阿托品眼藥水、角膜塑形鏡和矯正眼鏡等可用治療方法的了解不斷增加，正在推動市場擴張。對數位眼睛疲勞的擔憂和公共衛生措施促使眼部護理成為首要任務。由於對有效解決方案的需求不斷增加，近視治療市場正在迅速成長。

專科治療方法有限

許多尖端治療方法，例如阿托品眼藥水和角膜塑形術，並不常見，尤其是在農村地區。由於獲得有效治療方法的機會有限，患者開始依賴傳統的眼鏡或隱形眼鏡。高昂的價格和缺乏經驗進一步阻礙了人們廣泛獲得專科治療方法。此外，新興國家缺乏基礎設施和知識，阻礙了市場的發展。因此，儘管近視發病率不斷上升，但市場拓展潛力仍有限。

遠端醫療位眼保健解決方案

遠距會診有利於早期發現、快速矯正，進而降低高度近視的風險。在開立角膜塑形術和阿托品眼藥水等矯正療法時，人工智慧診斷工具可以提高準確性和效率。數位視覺治療計劃提供個人化的治療方法，可提高患者的依從性和治療效果。穿戴式科技和智慧型手機的廣泛使用使得能夠持續監測眼睛健康狀況並鼓勵主動管理。這些發展將提高近視治療的有效性和便利性，進而促進市場發展。

治療後併發症

LASIK和角膜塑形鏡片的副作用，例如眼睛乾澀、眩光、光暈和視力矯正退化，使人們不願意接受這些手術。角膜感染疾病、視網膜脫落等嚴重的副作用使得患者和相關人員更加擔心患者的安全。矯正手術和後續治療的需求增加了費用並限制了近視治療的機會。口碑和患者的負面經驗可能會阻止潛在患者尋求治療。結果，該行業面臨成長潛力下降和採用率下降的問題。

COVID-19 的影響

COVID-19 疫情對近視治療市場產生了重大影響，擾亂了供應鏈並推遲了選擇性眼科護理程序。由於遠距工作和線上學習而留在家中以及螢幕時間的增加，導致近視盛行率上升，尤其是在兒童中。雖然最初的限制措施導致患者諮詢和治療量下降，但隨著人們對眼睛健康的意識提高，疫情後需求飆升。角膜塑形術、阿托品眼藥水和創新矯正鏡片的進步正在推動近視管理解決方案的市場復甦和長期成長。

預計預測期內單純近視群體將佔最大比重

由於全球範圍內，尤其是在兒童和年輕人中，近視的盛行率不斷上升，預計簡單近視部分將在預測期內佔據最大的市場佔有率。螢幕使用時間的增加和戶外活動的減少是導致病例增加的原因之一，從而刺激了對矯正解決方案的需求。專用隱形眼鏡和角膜塑形術等光學治療的進步進一步推動了市場的成長。此外，低劑量阿托品等藥物介入的出現擴大了治療選擇。

預計預測期內，腸外藥物部分將以最高的複合年成長率成長。

在預測期內，由於提供先進的藥物傳遞方法，確保快速有效的治療結果，預計腸外藥物領域將實現最高的成長率。阿托品注射等注射療法可以為高風險近視患者持續釋放藥物並減緩病情進展。該領域受益於生物製藥和基因治療技術的進步，提高了精準度和功效。新型注射藥物研發投入的不斷增加以及監管部門的核准進一步推動了市場的成長。高度近視盛行率的上升推動了對腸外干預的需求，從而影響了市場。

佔比最大的地區：

在預測期內，由於近視患者數量的增加和對早期療育意識的不斷增強，預計北美將佔據最大的市場佔有率。角膜塑形術、阿托品眼藥水和雷射手術等先進治療方法越來越受歡迎。主要企業的存在、技術進步以及支持性醫療政策正在推動市場成長。隱形眼鏡和手術技術的創新增加了兒童近視管理的需求。由於其強大的醫療保健基礎設施和研究投入，美國佔據市場主導地位，其次是加拿大。

複合年成長率最高的地區：

由於螢幕使用時間的增加和對眼睛健康的認知的不斷提高，預計亞太地區在預測期內將呈現最高的複合年成長率。中國、日本和韓國等國家在先進的眼部保健解決方案和政府措施方面處於領先地位。角膜塑形鏡、阿托品眼藥水和外科手術的創新正在推動市場擴張。此外，可支配收入的增加和專門治療的可用性也促進了需求。隨著技術的不斷進步，市場有望繼續成長。

免費客製化服務：

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 主要企業的 SWOT 分析（最多 3 家公司）
  • 地理細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭性基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第 2 章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二手研究資料資訊來源
    • 先決條件

第3章 市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第 4 章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

第5章 全球近視治療市場按類型

  • 單純性近視
  • 嚴重近視
  • 病理性近視
  • 其他類型

第6章 全球近視治療市場依治療方法

  • 眼鏡
  • 隱形眼鏡
  • 屈光矯正手術
  • LASIK
  • 安慰劑
  • 角膜塑形術
  • 其他治療方法

7. 全球近視治療市場依給藥途徑分類

  • 口服
  • 腸外
  • 其他給藥途徑

第 8 章 全球近視治療市場（依年齡層）

  • 兒童近視
  • 成人近視

第9章 全球近視治療市場（依最終使用者）

  • 醫院藥房
  • 零售藥局和眼鏡店
  • 網路藥局
  • 眼科門診
  • 其他最終用戶

第 10 章 全球近視治療市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Johnson & Johnson Vision
  • Novartis AG
  • CooperVision
  • Bausch & Lomb
  • EssilorLuxottica
  • Carl Zeiss Meditec AG
  • Alcon
  • Hoya Corporation
  • Nidek Co., Ltd.
  • STAAR Surgical Company
  • Ziemer Ophthalmic Systems AG
  • Menicon Co., Ltd.
  • SynergEyes, Inc.
  • Abbott Medical Optics Inc.
  • Visioneering Technologies, Inc.
  • Lumenis Ltd.
  • NeoVista, Inc.
  • Presbia PLC
Product Code: SMRC28893

According to Stratistics MRC, the Global Myopia Treatment Market is accounted for $12523.10 billion in 2024 and is expected to reach $22661.58 billion by 2030 growing at a CAGR of 10.39% during the forecast period. Myopia treatment refers to various methods used to slow, stop, or correct nearsightedness, a condition where distant objects appear blurry while close objects remain clear. Treatment options include prescription eyeglasses or contact lenses, orthokeratology (corneal reshaping lenses), atropine eye drops, and refractive surgeries like LASIK or PRK. Myopia management strategies, especially in children, aim to slow progression using lifestyle changes such as increased outdoor activities and reduced screen time. Advances in myopia control focus on innovative lenses and pharmaceutical approaches to prevent high myopia-related complications like retinal detachment and glaucoma.

Market Dynamics:

Driver:

Growing awareness and diagnosis

Early case detection is being achieved by expanded screening initiatives in workplaces and schools. Improvements in diagnostic technologies allow for accurate identification and prompt action. Growing knowledge of available treatments, such as atropine drops, orthokeratology, and corrective glasses, accelerates market expansion. Concerns about digital eye strain and public health initiatives further motivate people to give eye care first priority. As a consequence of the growing need for efficient solutions, the market for myopia treatments is growing quickly.

Restraint:

Limited availability of specialized treatments

Many cutting-edge therapies, such atropine eye drops and orthokeratology, are not generally available, particularly in rural regions. Patients become dependent on traditional eyeglasses and contact lenses as a result of this limitation in access to efficient remedies. The broad use of specialised therapies is further discouraged by high prices and a lack of experience. Additionally, market progress is slowed in emerging nations by a lack of infrastructure and knowledge. Consequently, even if the frequency of myopia is rising, the market's potential for expansion is still limited.

Opportunity:

Telemedicine and digital eye health solutions

Remote consultations lower the risk of developing severe myopia by facilitating early identification and prompt correction. When prescribing remedial therapies like orthokeratology and atropine drops, AI-powered diagnostic tools improve accuracy and efficiency. Programs for digital vision therapy offer individualised treatment regimens that enhance patient compliance and results. Proactive management is encouraged by the increased use of wearable technology and smartphones, which provide ongoing monitoring of eye health. These developments thereby increase market growth by improving the effectiveness and convenience of myopia therapy.

Threat:

Post-treatment complications

The side effects of LASIK or ortho-k lenses, including as dry eyes, glare, halos, and regression of vision correction, discourage people from pursuing these procedures. Serious side effects, such as corneal infections and retinal detachment, make patients and medical professionals even more concerned about patient safety. Costs are raised by the requirement for corrective surgery and follow-up therapies, which limits access to myopia therapy. Word-of-mouth and unfavourable patient experiences deter potential patients from seeking care. Consequently, the industry is confronted with reduced growth potential and slower adoption rates.

Covid-19 Impact

The COVID-19 pandemic significantly impacted the myopia treatment market, disrupting supply chains and delaying elective eye care procedures. Lockdowns and increased screen time due to remote work and online learning contributed to rising myopia cases, especially among children. While initial restrictions led to reduced patient visits and treatment adoption, demand surged post-pandemic as awareness of eye health grew. Advancements in orthokeratology, atropine eye drops, and innovative corrective lenses gained traction, driving market recovery and long-term growth in myopia management solutions.

The simple myopia segment is expected to be the largest during the forecast period

The simple myopia segment is expected to account for the largest market share during the forecast period, due to its rising global prevalence, especially among children and young adults. Increasing screen time and reduced outdoor activities contribute to the growing cases, fuelling demand for corrective solutions. Advancements in optical treatments, such as specialized contact lenses and orthokeratology, further boost market growth. Additionally, the availability of pharmacological interventions like low-dose atropine expands treatment options.

The parenteral segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the parenteral segment is predicted to witness the highest growth rate by offering advanced drug delivery methods that ensure rapid and effective therapeutic outcomes. Injectable treatments, such as atropine injections, provide sustained drug release, reducing progression in high-risk myopic patients. This segment benefits from technological advancements in biologics and gene therapy, enhancing precision and efficacy. Increased R&D investments and regulatory approvals for novel injectables further drive market growth. The rising prevalence of severe myopia cases boosts demand for parenteral interventions, reinforcing their market impact.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to rising cases of myopia and growing awareness of early intervention. Advanced treatments like orthokeratology, atropine eye drops, and laser surgery are gaining traction. The presence of key players, technological advancements, and supportive healthcare policies drive market growth. The demand for pediatric myopia management is increasing, with innovations in contact lenses and surgical options. The U.S. dominates the market, followed by Canada, due to strong healthcare infrastructure and research investments.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, owing to increasing screen time and growing awareness about eye health. Countries like China, Japan, and South Korea are at the forefront, driven by advanced eye care solutions and government initiatives. Innovations in orthokeratology lenses, atropine eye drops, and surgical procedures fuel market expansion. Additionally, rising disposable incomes and the availability of specialized treatments contribute to demand. The market is poised for continuous growth with ongoing technological advancements.

Key players in the market

Some of the key players profiled in the Myopia Treatment Market include Johnson & Johnson Vision, Novartis AG, CooperVision, Bausch & Lomb, EssilorLuxottica, Carl Zeiss Meditec AG, Alcon, Hoya Corporation, Nidek Co., Ltd., STAAR Surgical Company, Ziemer Ophthalmic Systems AG, Menicon Co., Ltd., SynergEyes, Inc., Abbott Medical Optics Inc., Visioneering Technologies, Inc., Lumenis Ltd., NeoVista, Inc. and Presbia PLC.

Key Developments:

In December 2024, EssilorLuxottica agreed to acquire Espansione Group, an Italy-based company specializing in non-invasive medical devices for diagnosing and treating dry-eye, ocular surface, and retinal diseases. This acquisition aims to strengthen EssilorLuxottica's position in the med-tech sector and enhance its portfolio of vision care solutions.

In July 2024, EssilorLuxottica announced the acquisition of a majority stake in Heidelberg Engineering, a German company specializing in ophthalmic diagnostic instruments. This acquisition is expected to bolster EssilorLuxottica's capabilities in providing comprehensive diagnostic and surgical solutions, supporting early diagnosis and treatment of eye conditions, including myopia.

In May 2023, EssilorLuxottica partnered with Chalhoub Group to form a joint venture focused on expanding retail eyewear presence in the Gulf Cooperation Council (GCC) region. The collaboration plans to open mono-brand and multi-brand stores for iconic global brands such as Ray-Ban, Persol, Oliver Peoples, and David Clulow, aiming to enhance customer service and experiences in the region.

Types Covered:

  • Simple Myopia
  • High Myopia
  • Pathological Myopia
  • Other Types

Treatments Covered:

  • Eyeglasses
  • Contact Lenses
  • Refractive Surgery
  • LASIK
  • PRK
  • Ortho-K
  • Other Treatments

Route of Administrations Covered:

  • Oral
  • Parenteral
  • Other Route of Administrations

Age Groups Covered:

  • Pediatric Myopia
  • Adult Myopia

End Users Covered:

  • Hospital Pharmacies
  • Retail Pharmacies & Optical Stores
  • Online Pharmacies
  • Ophthalmology Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Myopia Treatment Market, By Type

  • 5.1 Introduction
  • 5.2 Simple Myopia
  • 5.3 High Myopia
  • 5.4 Pathological Myopia
  • 5.5 Other Types

6 Global Myopia Treatment Market, By Treatment

  • 6.1 Introduction
  • 6.2 Eyeglasses
  • 6.3 Contact Lenses
  • 6.4 Refractive Surgery
  • 6.5 LASIK
  • 6.6 PRK
  • 6.7 Ortho-K
  • 6.8 Other Treatments

7 Global Myopia Treatment Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Parenteral
  • 7.4 Other Route of Administrations

8 Global Myopia Treatment Market, By Age Group

  • 8.1 Introduction
  • 8.2 Pediatric Myopia
  • 8.3 Adult Myopia

9 Global Myopia Treatment Market, By End User

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies & Optical Stores
  • 9.4 Online Pharmacies
  • 9.5 Ophthalmology Clinics
  • 9.6 Other End Users

10 Global Myopia Treatment Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Johnson & Johnson Vision
  • 12.2 Novartis AG
  • 12.3 CooperVision
  • 12.4 Bausch & Lomb
  • 12.5 EssilorLuxottica
  • 12.6 Carl Zeiss Meditec AG
  • 12.7 Alcon
  • 12.8 Hoya Corporation
  • 12.9 Nidek Co., Ltd.
  • 12.10 STAAR Surgical Company
  • 12.11 Ziemer Ophthalmic Systems AG
  • 12.12 Menicon Co., Ltd.
  • 12.13 SynergEyes, Inc.
  • 12.14 Abbott Medical Optics Inc.
  • 12.15 Visioneering Technologies, Inc.
  • 12.16 Lumenis Ltd.
  • 12.17 NeoVista, Inc.
  • 12.18 Presbia PLC

List of Tables

  • Table 1 Global Myopia Treatment Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Myopia Treatment Market Outlook, By Type (2022-2030) ($MN)
  • Table 3 Global Myopia Treatment Market Outlook, By Simple Myopia (2022-2030) ($MN)
  • Table 4 Global Myopia Treatment Market Outlook, By High Myopia (2022-2030) ($MN)
  • Table 5 Global Myopia Treatment Market Outlook, By Pathological Myopia (2022-2030) ($MN)
  • Table 6 Global Myopia Treatment Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 7 Global Myopia Treatment Market Outlook, By Treatment (2022-2030) ($MN)
  • Table 8 Global Myopia Treatment Market Outlook, By Eyeglasses (2022-2030) ($MN)
  • Table 9 Global Myopia Treatment Market Outlook, By Contact Lenses (2022-2030) ($MN)
  • Table 10 Global Myopia Treatment Market Outlook, By Refractive Surgery (2022-2030) ($MN)
  • Table 11 Global Myopia Treatment Market Outlook, By LASIK (2022-2030) ($MN)
  • Table 12 Global Myopia Treatment Market Outlook, By PRK (2022-2030) ($MN)
  • Table 13 Global Myopia Treatment Market Outlook, By Ortho-K (2022-2030) ($MN)
  • Table 14 Global Myopia Treatment Market Outlook, By Other Treatments (2022-2030) ($MN)
  • Table 15 Global Myopia Treatment Market Outlook, By Route of Administration (2022-2030) ($MN)
  • Table 16 Global Myopia Treatment Market Outlook, By Oral (2022-2030) ($MN)
  • Table 17 Global Myopia Treatment Market Outlook, By Parenteral (2022-2030) ($MN)
  • Table 18 Global Myopia Treatment Market Outlook, By Other Route of Administrations (2022-2030) ($MN)
  • Table 19 Global Myopia Treatment Market Outlook, By Age Group (2022-2030) ($MN)
  • Table 20 Global Myopia Treatment Market Outlook, By Pediatric Myopia (2022-2030) ($MN)
  • Table 21 Global Myopia Treatment Market Outlook, By Adult Myopia (2022-2030) ($MN)
  • Table 22 Global Myopia Treatment Market Outlook, By End User (2022-2030) ($MN)
  • Table 23 Global Myopia Treatment Market Outlook, By Hospital Pharmacies (2022-2030) ($MN)
  • Table 24 Global Myopia Treatment Market Outlook, By Retail Pharmacies & Optical Stores (2022-2030) ($MN)
  • Table 25 Global Myopia Treatment Market Outlook, By Online Pharmacies (2022-2030) ($MN)
  • Table 26 Global Myopia Treatment Market Outlook, By Ophthalmology Clinics (2022-2030) ($MN)
  • Table 27 Global Myopia Treatment Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.